Teleflex Incorporated (TFX) News
Follow Teleflex Incorporated (TFX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 29 public stories across 15 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Teleflex 3Q 2026: Revenue $567.78M, EPS $22.28 — 10-Q Summary
Teleflex's third-quarter revenue was essentially flat year over year, while net income turned positive, driven primarily by the gain on sale of its OEM business in discontinued operations. Continuing-operations gross mar
EARNINGS | Nov 05, 2026, 05:01 PM UTC
M
Teleflex Reports Higher Q3 Adjusted Earnings and Revenue
Teleflex reported higher adjusted earnings and revenue for Q3.
EQUITY | Nov 05, 2026, 01:25 PM UTC
M
Teleflex Reports Q3 Revenue of $567.8 Million
Teleflex reported Q3 revenue of $567.8 million, versus a FactSet estimate of $565.5 million.
EQUITY | Nov 05, 2026, 11:42 AM UTC
M
Teleflex Expects 2026 Adjusted EPS of $7.50–$7.75
Teleflex expects 2026 adjusted EPS of $7.50 to $7.75, versus a FactSet estimate of $7.22.
EARNINGS | Nov 05, 2026, 11:42 AM UTC
M
Teleflex Reports Third-Quarter Results and Full-Year 2026 Outlook
EQUITY | Nov 05, 2026, 11:32 AM UTC
M
Teleflex Q3 continuing-operations EPS is $1.30
EARNINGS | Nov 05, 2026, 11:31 AM UTC
M
Teleflex Q3'26 Results Preview: Revenue Estimated at 565.38 Million USD
Teleflex is scheduled to report Q3'26 results on October 22; the report time is not specified. Revenue is estimated at 565.38 million USD, with EPS anticipated at 1.90 USD.
EQUITY | Oct 15, 2026, 11:01 AM UTC
H
Full Transcript: Teleflex Q2 2026 Earnings Call
Teleflex (NYSE: TFX ) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you APIs. For real-time a
LIVE | Oct 08, 2026, 08:14 AM UTC
L
Teleflex Incorporated (TFX) Study Shows 70% Lower CLABSI Hazard With Arrowg+ard
Teleflex reported a peer-reviewed multinational study of 1,750 critically ill patients showing Arrowg+ard-protected CVCs had a 70% lower CLABSI hazard vs plain catheters over 30 days (HR 0.297; 95% CI 0.134-0.658; p=0.00
NEWS | Sep 29, 2026, 10:30 AM UTC
L
Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology
Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the publication of its latest peer-reviewed study in the American Journal of Infection Control demonstrating that Centr
NEWS | Sep 29, 2026, 10:30 AM UTC
L
Nyxoah Appoints Liam Kelly as Chief Executive Officer
REGULATED INFORMATIONINSIDE INFORMATIONNyxoah Appoints Liam Kelly as Chief Executive OfficerFurther strengthening the Company’s strategic U.S. presence and focusMont-Saint-Guibert, Belgium — September 28, 2026, 10:30 pm
NEWS | Sep 28, 2026, 08:32 PM UTC
L
Why Teleflex (TFX) Stock Is Trading Up Today
What Happened? Shares of medical technology company Teleflex NYSE:TFXjumped 4.5% in the afternoon session after BofA Securities upgraded the stock from Neutral to Buy and raised its price target.BofA Securities analyst C
EQUITY | Sep 28, 2026, 08:11 PM UTC
L
Here are Monday's biggest analyst calls: Nvidia, SpaceX, Apple, Micron, Coinbase, Tesla, Sweetgreen & more
Here are Monday's biggest calls on Wall Street:JPMorgan reiterates Apple as overweightJPMorgan said its checks show Apple's iPhone lead times are healthy."While high lead times at this point in the cycle are not uncommon
NEWS | Sep 28, 2026, 01:18 PM UTC
L
Teleflex Price Target Raised to $158.00/Share From $145.00 by B of A Securities
Ratings actions from Benzinga
NEWS | Sep 28, 2026, 10:50 AM UTC
L
Teleflex elects Sean M. Salmon to board, committee
Teleflex elected Sean M. Salmon to its board and named him to the Growth and Operating Committee after expanding the board to nine members.
REGULATION | Sep 09, 2026, 10:05 AM UTC
L
Teleflex appoints Sean Salmon to board
Teleflex appointed Sean Salmon to its board, according to TradingView News.
EQUITY | Sep 08, 2026, 10:30 AM UTC
L
Teleflex appoints Sean M. Salmon to board effective Sept. 8, 2026
Teleflex Incorporated appointed medical technology executive Sean M. Salmon to its Board of Directors, effective September 8, 2026.
EQUITY | Sep 08, 2026, 10:30 AM UTC
L
TFX - Teleflex Features Innovative Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System at CIRSE 2026
TFX - Teleflex Features Innovative Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System at CIRSE 2026
EQUITY | Sep 04, 2026, 10:31 AM UTC
L
Teleflex to showcase Dynetiс-35 stent system at CIRSE 2026
Teleflex (TFX) said it will showcase innovative technologies at CIRSE 2026 in Copenhagen, including its Dynetiс-35 balloon-expandable cobalt chromium stent system.
EQUITY | Sep 04, 2026, 10:30 AM UTC
L
UBS Raises Teleflex Price Target
UBS raises Teleflex price target to $158 from $145
EQUITY | Aug 11, 2026, 09:07 PM UTC
L
TFX - Teleflex Reports Second Quarter Financial Results and Full Year 2026 Outlook
TFX - Teleflex Reports Second Quarter Financial Results and Full Year 2026 Outlook
EARNINGS | Aug 06, 2026, 10:41 AM UTC
L
Teleflex Raises FY2026 Adj EPS Guidance from $6.25-$6.55 to $6.90-$7.20 vs $6.68 Est; Lowers FY2026 Sales Guidance from $2.280B-$2.300B to $
Teleflex (NYSE: TFX ) raises FY2026 Adj EPS guidance from $6.25-$6.55 to $6.90-$7.20 vs $6.68 analyst estimate. Lowers FY2026 sales outlook from $2.280 billion-$2.300 billion to $2.260 billion-$2.280 billion vs $2.287 bi
EARNINGS | Aug 06, 2026, 10:36 AM UTC
H
Teleflex Sells OEM Business for $1.5 Billion
Teleflex divests OEM business
MNA | Aug 03, 2026, 08:21 PM UTC
L
TFX Teleflex announces FDA BLA approval of ezplaz™ freeze dried plasma Teleflex announces FDA BLA approval of ezplaz™ freeze dried plasma Te
TFX Teleflex announces FDA BLA approval of ezplaz™ freeze dried plasma Teleflex announces FDA BLA approval of ezplaz™ freeze dried plasma Teleflex Inc: announces FDA BLA approval of ezplaz™ freeze dried plasma
REGULATION | Jul 29, 2026, 08:15 PM UTC
L
TFX US FDA - licenses first freeze-dried plasma product ezplaz in the United States - Ezplaz available in group Ab and group a low-titer ant
TFX US FDA - licenses first freeze-dried plasma product ezplaz in the United States - Ezplaz available in group Ab and group a low-titer anti-b for emergency transfusion
REGULATION | Jul 29, 2026, 04:15 PM UTC
L
TFX Initiated Neutral W/$145.00 PT at UBS
TFX Initiated Neutral W/$145.00 PT at UBS
EQUITY | Jul 28, 2026, 11:49 AM UTC
L
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: O
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: OUTPERFORM @ Wedbush CRWD: BUY @ Loop FTH: OUTPERFORM @ Opp HRB: EQUAL WEIGHT @ S
EQUITY | Jul 28, 2026, 11:11 AM UTC
L
Teleflex awarded national central venous access agreement with Premier
Teleflex awarded national central venous access agreement with Premier
EQUITY | Jul 21, 2026, 12:50 PM UTC
M
TFX Initiates Enrollment
Teleflex initiates enrollment in global BIOMAG-III pivotal trial of Freesolve resorbable magnesium scaffold
EQUITY | Jun 23, 2026, 10:30 AM UTC